Cytokinetics
Aficamten, a cardiac muscle myosin activator small molecule therapeutic
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 23
- 17 pending · first 2024
- Rank in peer group#28 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#28 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 23 granted of 40- New patentNampt ModulatorsUSPTOUS 12,747,203
- PendingSalt Of Omecamtiv Mecarbil And Process For Preparing SaltUSPTOApplication 19431952
- GrantedPolymorphs Of (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDEUSPTOUS 12,649,732
Show all 40 patent records
- Nampt ModulatorsSep 29, 2026 · US 12,747,203Granted
- Salt Of Omecamtiv Mecarbil And Process For Preparing SaltAug 6, 2026 · Application 19431952Pending
- Polymorphs Of (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDEJun 9, 2026 · US 12,649,732Granted
- Pyrazole Derivatives Useful As Nampt ModulatorsJun 9, 2026 · US 12,649,729Granted
- Methods For Treating Hypertrophic CardiomyopathyApr 9, 2026 · Application 19257352Pending
- Bicyclic 1,4-DIAZEPANONES And Therapeutic Uses ThereofApr 9, 2026 · Application 19261878Pending
- Salt Of Omecamtiv Mecarbil And Process For Preparing SaltMar 24, 2026 · US 12,583,821Granted
- Indane And Coumaran Derivatives As Fast Skeletal Muscle Myosin InhibitorsFeb 26, 2026 · Application 19104150Pending
- Heterocyclic Compounds And Their UsesDec 11, 2025 · Application 19029911Pending
- Bicyclic 1,4-DIAZEPANONES And Therapeutic Uses ThereofOct 14, 2025 · US 12,441,691Granted
- Bicyclic Piperazinones And Therapeutic Uses ThereofSep 25, 2025 · Application 18862138Pending
- Methods For Treating Heart DiseasesSep 25, 2025 · Application 19002411Pending
- Cardiac Sarcomere InhibitorsSep 4, 2025 · Application 19014118Pending
- Methods Of Treating Heart Failure With Cardiac Sarcomere ActivatorsAug 14, 2025 · Application 19183619Pending
- Salt Of Omecamtiv Mecarbil And Process For Preparing SaltJul 31, 2025 · Application 18990483Pending
- Methods For Treating Hypertrophic CardiomyopathyJul 29, 2025 · US 12,370,179Granted
- Methods For Treating Hypertrophic CardiomyopathyJun 5, 2025 · Application 18916215Pending
- Methods Of Treating Heart Failure With Cardiac Sarcomere ActivatorsMay 13, 2025 · US 12,295,952Granted
- Cardiac Sarcomere InhibitorsApr 29, 2025 · US 12,286,437Granted
- Heterocyclic Compounds And Their UsesApr 15, 2025 · US 12,275,704Granted
- Cardiac Sarcomere InhibitorsApr 15, 2025 · US 12,275,741Granted
- Process For Preparing AficamtenMar 11, 2025 · US 12,247,024Granted
- Cardiac Sarcomere InhibitorsFeb 20, 2025 · Application 18762390Pending
- Salt Of Omecamtiv Mecarbil And Process For Preparing SaltFeb 11, 2025 · US 12,221,417Granted
- Polymorphs And Cocrystals Of A Cardiac Troponin ActivatorJan 7, 2025 · US 12,187,700Granted
- Cardiac Sarcomere InhibitorsJan 7, 2025 · US 12,187,712Granted
- Nampt ModulatorsAug 22, 2024 · Application 18393327Pending
- Cardiac Sarcomere InhibitorsAug 20, 2024 · US 12,065,436Granted
- Methods For Treating Heart Failure By Administering Cardiac Sarcomere ActivatorsMay 21, 2024 · US 11,986,474Granted
- Bisamide Sarcomere Activating Compounds And Uses ThereofMay 16, 2024 · Application 18451757Pending
- Bicyclic 1,4-DIAZEPANONES And Therapeutic Uses ThereofMay 14, 2024 · US 11,981,644Granted
- Crystalline Forms Of 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDEApr 25, 2024 · Application 18460314Pending
- Cardiac Sarcomere InhibitorsApr 23, 2024 · US 11,964,967Granted
- Salt Of Omecamtiv Mecarbil And Process For Preparing SaltApr 16, 2024 · US 11,958,809Granted
- Methods For Treating Obstructive Hypertrophic CardiomyopathyApr 11, 2024 · Application 18365038Pending
- Cardiac Sarcomere InhibitorsApr 9, 2024 · US 11,952,381Granted
- Methods For Treating Non-obstructive Hypertrophic CardiomyopathyMar 21, 2024 · Application 18355195Pending
- Process For Preparing AficamtenMar 19, 2024 · US 11,932,631Granted
- Methods Of Treating Heart Failure With Cardiac Sarcomere ActivatorsMar 19, 2024 · US 11,931,358Granted
- Cardiac Sarcomere InhibitorsMar 5, 2024 · US 11,919,909Granted
Related companies, and why
- Valora TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Exthymic CorpSimilar federal contract value in Biotech · null in contracts
- RECOMBINATION THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- CurlBio LLCSimilar federal contract value in Biotech · null in contracts
- DMK PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- CHROMOCELL CORPORATIONSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .